Lupin receives tentative approval for Efinaconazole Topical Solution

Lupin Limited (NSE: Lupin), global pharmaceutical company, announced today that it has received tentative approval for its Efinaconazole Topical Solution, 10%, from the United States Food and Drug Administration, to market a generic equivalent of Jublia® Topical Solution, 10%, of Bausch Health Americas, Inc.

Efinaconazole Topical Solution, 10%, is indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.

Efinaconazole Topical Solution, 10%, (RLD: Jublia®) had estimated annual sales of USD 222.9 million in the U.S. (IQVIA MAT September 2020).

Shares of LUPIN LTD. was last trading in BSE at Rs.978 as compared to the previous close of Rs. 963. The total number of shares traded during the day was 89580 in over 2780 trades.

The stock hit an intraday high of Rs. 981.6 and intraday low of 962. The net turnover during the day was Rs. 87165178.

Source : Equity Bulls

Keywords